Pseudomonas aeruginosa acquires extracellular heme via the Phu (Pseudomonas heme uptake) and Has (heme assimilation system) systems. We have previously shown the catalytic actions of heme oxygenase (HemO) along with the cytoplasmic heme transport protein PhuS control heme flux into the cell. To further investigate the role of the PhuS-HemO couple in modulating heme uptake, we have characterized two HemO variants, one that is catalytically inactive (HemO H26A/K34A/K132A or HemO in ) and one that has altered regioselectivity (HemO N19K/K34A/F117Y/K132A or HemO ␣ ), producing biliverdin IX␣ (BVIX␣). HemO ␣ similar to wild type was able to interact and acquire heme from holo-PhuS. In contrast, the HemO in variant did not interact with holo-PhuS and showed no enzymatic activity. Complementation of a hemO deletion strain with the hemO in or hemO ␣ variants in combination with [ 13 C]heme isotopic labeling experiments revealed that the absence of BVIX␤ and BVIX␦ leads to a decrease in extracellular levels of hemophore HasA. We propose BVIX␤ and/or BVIX␦ transcriptionally or post-transcriptionally regulates HasA. Thus, coupling the PhuS-dependent flux of heme through HemO to feedback regulation of the cell surface signaling system through HasA allows P. aeruginosa to rapidly respond to fluctuating extracellular heme levels independent of the iron status of the cell. . 3 The abbreviations used are: ECF, extracytoplasmic function; HemO, heme oxygenase; phu, Pseudomonas heme uptake; has, heme assimilation system; HemO in , HemO H26A/K34A/K132A; HemO ␣ HemO N19K/K34A/
Iron is an essential micronutrient for the survival and virulence of Gram-negative pathogens (1) (2) (3) (4) . Many pathogens, including the opportunistic pathogen Pseudomonas aeruginosa, encode systems that utilize the host heme-containing proteins as a source of iron (5, 6) . P. aeruginosa encodes two heme uptake systems, the Pseudomonas heme uptake (phu) and the heme assimilation system (has). The phu system encodes a TonB-dependent outer membrane receptor (PhuR) that transports heme to the periplasm, where a soluble heme-binding protein (PhuT) interacts with an ATP-dependent permease (ABC transporter) (PhuUV), which then translocates heme to the cytoplasmic heme-binding protein (PhuS). In contrast the has operon encodes a soluble secreted hemophore (HasA) that scavenges heme and transfers it to the TonB-dependent outer membrane receptor (HasR) (7) (8) (9) . In Serratia marcescens HasA and HasR additionally function in cell surface signaling by sensing heme and transmitting the signal through HasR to the extracytoplasmic function (ECF) 3 system (HasS/HasI) (10) . We have recently shown through a combination of bacterial genetics and [ 13 C]heme metabolite studies that HasR functions primarily as a heme sensor, whereas PhuR is the major heme transporter (11) .
Once translocated into the cell, heme is sequestered by the cytoplasmic binding protein PhuS and transferred to the BVIX␤/␦ regioselective HemO. We have previously shown deletion of hemO shuts down the flux of extracellular heme into the cell despite up-regulation of the heme transport system (12) . In contrast, deletion of phuS leads to inefficient heme utilization at low heme concentration, whereas at higher heme concentrations heme is degraded through both HemO and the bacterial phytochrome-associated BVIX␣selective BphO (13) . The shunting of heme through both HemO and BphO is consistent with previous in vitro studies that have shown PhuS specifically interacts with HemO but not BphO (14) . We concluded from these studies that PhuS and HemO are metabolically coupled to regulate heme flux into the cell.
To further dissect the role of the PhuS-HemO couple in driving and regulating extracellular heme flux, we have characterized two HemO variants, one that is catalytically inactive HemO in and the other that has altered regioselectivity HemO ␣ , producing biliverdin IX␣ (BVIX␣). We confirmed the previous observation that a catalytic HemO is required to drive extracellular heme uptake into the cell. Furthermore, we show the HemO-derived BVIX␤ and BVIX␦ metabolites act as positive feedback regulators of the extracellular hemophore, HasA. The studies herein suggest a mechanism that couples the regulation heme flux through PhuS-HemO to transcriptional and/or post-transcriptional regulation of the has operon that allows the cell to rapidly adapt to changes in extracellular heme levels.
Results
Characterization of the HemO in and HemO ␣ Proteins-The crystal structure of the P. aeruginosa holo-HemO revealed the unique BVIX␤/␦ regioselectivity was the result of a 90°inplane rotation of the heme compared with the BVIX␣-selective enzymes (15) . To generate a BVIX␣-selective HemO, we mutated the heme propionate coordinating Lys-34 and Lys-132 residues of HemO to Ala, and we introduced alternative propionate interactions through mutation of Asn-19 to Lys and Phe-117 to Tyr as seen in the BVIX␣-selective Neisseriae meningitidis HemO (16) . To generate the inactive enzyme HemO in , we removed the proximal His-26 in addition to the residues critical in anchoring the heme (Lys-34 and Lys-132). The HemO mutants expressed and purified as for the WT protein. The structural integrity of the purified HemO variants was confirmed by CD spectroscopy. The spectra of apo-HemO ␣ and HemO in show proteins with ␣-helical content similar to that of the WT protein ( Fig. 1A ). Thermal denaturation curves show a single transition on unfolding with T m values for the WT, HemO in , and HemO ␣ within the range 54 -56°C (Fig. 1B) . The similar T m values indicate the intrinsic thermal stability of the mutant HemO proteins are not significantly different from the WT. The UV-visible absorption spectrum shows a Soret band at 407 nm for the WT and a slightly blue-shifted Soret band at 404 nm for the HemO ␣ protein (Fig. 1C ). As expected, the HemO in on addition of a molar equivalent of heme gave a spectrum with a peak at 398 nm typical of non-protein coordinated aqua heme (Fig. 1C) .
Holo-PhuS Interacts with HemO ␣ but Not HemO in -As reported previously, titration of apo-HemO with holo-PhuS gave a negative enthalpic signal with a 1:1 stoichiometry and an apparent K a of 5.4 ϫ 10 5 M Ϫ1 (Table 1) (14) . Similarly, interaction of holo-PhuS with apo-HemO ␣ gave a favorable binding enthalpy with a K a value similar to that for the wild type HemO ( Fig. 2A and Table 2 ). In contrast, the titration of holo-PhuS with HemO in is entropically driven and indicative of a nonspecific hydrophobic interaction (Fig. 2B ). The inability of the HemO in variant to interact with holo-PhuS and transfer heme suggests the charged residues required for anchoring heme within the HemO active site may also be required for proteinprotein interaction and transfer of heme from holo-PhuS.
Heme Utilization in the ⌬hemO Complemented Strains-We have previously shown deletion of the hemO gene shuts down extracellular heme flux into the cell (12) . To understand the potential role of HemO regioselectivity in regulating heme flux into the cell, we complemented the ⌬hemO strain with the BVIX␣ regioselective hemO ␣ and a catalytically inactive hemO in gene at the phage attachment (attB) site. For comparative purposes, we also cloned the hemO wt gene into the attB site. All of the strains grew at similar rates in iron-depleted M9 media (Fig. 3A ). On addition of 0.5 M heme, the strains grew at an increased rate, although the ⌬hemO complemented strains lagged WT PAO1.
To address the differences in growth rate between strains, we tested the ability of the complemented strains to utilize extracellular heme as an iron source under the same growth conditions. We have previously shown that supplementation with 0.5 M [ 13 C]heme as the sole source of iron is sufficient to detect BVIX metabolites and does not lead to Fur repression of the heme uptake systems within 3-5 h (11, 12) . As reported previously, analysis of the BVIX metabolites in PAO1 at 5 h yields predominantly extracellular [ 13 C]heme-derived BVIX␤ and BVIX␦ ( Fig. 3B) (12) . The peak in extracellular heme-derived [ 13 C]BVIX is consistent with the increase in intracellular iron at 2 h as measured by ICP-MS ( Fig. 3D ). We expect to see a lag between peak intracellular iron and extracellular BVIX levels. At the 7-h time point, the ratio of [ 13 C]heme to [ 12 C]hemederived BVIX␤ and BVIX␦ is close to 50% (Fig. 3C ). The increase in 12 C-derived BVIX metabolites is also consistent with the lower intracellular iron levels between 5-7 h as heme becomes limiting ( Fig. 3D ). In contrast, the ⌬hemO::hemO wt strain showed a lag in extracellular [ 13 C]BVIX␤ and [ 13 C]-BVIX␦ levels and as a consequence decreased intracellular iron levels compared with PAO1 ( Fig. 3, B and D) . Despite the fact the differences in mRNA and protein levels of the heme uptake proteins and HemO are not physiologically significant, the complemented strain is unable to utilize heme as efficiently as the WT PAO1 as shown by the lag in growth (Fig. 3A ).
The hemO::hemO ␣ strain was able to utilize heme as efficiently as PAO1 as shown by the comparable levels of [ 13 C]BVIX␣ to [ 13 C]BVIX␤ and -BVIX␦ at 5 h ( Fig. 3B ). However, despite the ability to utilize [ 13 C]heme, the intracellular iron levels did not increase over the first 2 h as observed for WT PAO1 (Fig. 3D) .
In contrast, the ⌬hemO::hemO in strain is unable to acquire extracellular [ 13 C]heme in the absence of a catalytically active HemO as confirmed by the lack of [ 13 C]BVIX metabolites and a progressive decrease in intracellular iron levels over time ( 
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3, B and D). These results as observed previously for the ⌬hemO knock-out confirm that the lack of HemO activity cannot be compensated for by the alternative BVIX␣-selective heme oxygenase, BphO (12) . At the 7-h time point, background levels of BVIX are detected in the extracellular media, a result of nonspecific heme degradation and release of iron by redox-active molecules (Fig. 3C ). These redox-active molecules include pyocyanin and phenazines that are secreted in higher amounts in the ⌬hemO and ⌬hemO::hemO in mutant strains (data not shown). Interestingly, the inability to utilize heme and the lack of [ 13 C]BVIX␦ and -BVIX␤ is accompanied by a down-regulation in both hemO in mRNA and protein expression ( Fig. 4B ).
We have previously shown PhuR is the major heme transporter (11) , and PhuS is required for regulation of heme flux through HemO (12) . Therefore, to confirm that the decreased efficiency in heme utilization by the hemO::hemO wt and hemO::hemO ␣ strains was not due to changes in the expression levels of PhuR and PhuS, we analyzed the mRNA and protein levels in each of the strains. As shown in Fig. 5 , the difference in PhuR mRNA levels was not physiologically significant as the protein expression was similar in all strains ( Fig. 5B ). Although the protein expression levels of PhuS show variation between strains following initial iron starvation, on addition of 0.5 M heme the mRNA and protein expression profiles between 2 and 7 h are similar ( Fig. 6 ). Therefore, the lag in growth and decrease in the ability to efficiently utilize heme in the hemO::hemO wt and hemO::hemO ␣ strains is not due to decreased expression of the major heme transporter PhuR or heme flux through PhuS. It is unclear at this time why complementation with hemO wt at the phage site does not restore heme utilization efficiency to that of PAO1. However, as will be outlined below, there exists an underlying link between BVIX␦ and BVIX␤ metabolite levels and the regulation of the hemophore HasA. The consequence of decreased BVIX␦ and/or BVIX␤ leads to a decrease in HasA and the cells' ability to sense extracellular heme.
Heme and BVIX-dependent Regulation of hasA and hasR-The P. aeruginosa-encoded has ECF -factor signaling cascade like that of S. marcescens is thought to autoregulate the hasA and hasR genes in response to heme (10) . Consistent with activation of the ECF signaling cascade by the heme-loaded HasA, the hasA and hasR mRNA levels show a time-dependent increase on addition of heme to the media (Figs. 7A and 8A). In PAO1, the steady state mRNA levels of HasA and HasR peak at 5 h with an ϳ100and ϳ10-fold increase, respectively. As the cells are washed and resuspended in fresh media prior to the addition of [ 13 C]heme, there is a lag before the appearance of HasA in the extracellular medium ( Fig. 7B ). Protein expression of HasA peaks at 5 h consistent with the mRNA profile ( Fig. 7A ) and [ 13 C]BVIX␦ and -BVIX␤ levels (Fig. 3B) . A similar protein expression profile is observed for the complemented ⌬hemO:: hemO wt strain, although there is an initial lag in hasA mRNA levels and protein expression compared with PAO1 ( Fig. 7) . The lag in up-regulation of hasA coincides with the reduced extracellular [ 13 C]BVIX␤ and [ 13 C]BVIX␦ metabolites and lower intracellular iron compared with the parent PAO1 strain (Fig. 3, B and D) . The decreased levels of extracellular HasA as a function of lower BVIX␤ and BVIX␦ metabolites were confirmed in the hemO::hemO in strain where HasA protein levels are significantly reduced over the first 5 h (Fig. 7B ).
Although the hemO:hemO ␣ strain can utilize heme as efficiently as the parent PAO1 strain as judged by the similar overall BVIX levels in first 5 h (Fig. 3B ), the extracellular HasA protein levels are significantly lower than in PAO1 (Fig. 7B ). The lag in HasA protein levels in strains lacking a BVIX␤/␦ regioselective HemO (⌬hemO::hemO in and hemO::hemO ␣ ) suggests one or both isomers may play a role in the regulation of hasA. Interestingly, the hasR steady state mRNA and protein levels in the complemented strains lag PAO1, presumably a result of the reduced levels of HasA dampening down activation of the -factor HasI (Fig. 8 ). The similar levels of HasA in all strains at the 7-h time point is due to derepression of Fur on iron limitation as extracellular heme becomes limiting ( Fig. 3D ). We conclude that hasA independent of hasR is regulated by heme flux through the BVIX␤ and BVIX␦ regioselective HemO.
Discussion
Based on our previous findings that PhuS acts as the regulator of heme flux through HemO, we hypothesized the alternative BVIX␤ and BVIX␦ regioselectivity may play a role in regulating extracellular heme uptake (12, 14) . However, complementation of the ⌬hemO strain at the phage integration locus with the hemO wt gene did not fully recover wild type levels of heme metabolites. When grown in low iron, the steady state hemO mRNA levels of the ⌬hemO::hemO wt strain lag those of PAO1 ( Fig. 3B ). It is unclear at this time why complementation of the hemO gene at the attB site does not restore heme utilization efficiency to that of PAO1. It is possible that there are post-transcriptional regulatory elements within the hemO locus that are not within the currently defined promoter region. Regardless of the reason, complementation of the ⌬hemO strain with the hemO wt gene at the attB site ultimately leads to reduced BVIX␤ and BVIX␦ and points to a potential metabolite-driven regulation of hasA. This was further supported on complementation of the PAO1 ⌬hemO strain with the catalytically inactive HemO in enzyme where the lack of BVIX metabolites correlated with reduced HasA protein levels. The BVIX␣selective hemO::hemO␣ strain also shows a significant decrease in HasA expression compared with PAO1. Therefore, regulation of hasA is not due to the overall level of BVIX metabolites but is dependent specifically on the levels of HemO-derived BVIX␤ and/or BVIX␦ isomers.
As for S. marcescens, the extracellular heme is proposed to activate the Has system through a cell surface signaling cascade.
In the presence of heme, holo-HasA interacts with the HasR receptor and activates the cell surface signaling cascade releasing the HasI -factor that then activates hasA and hasR expression ( Figs. 7A and 8A ). However, we noted the induction of hasA mRNA is almost 10-fold greater than that of hasR suggesting a separate and distinct mechanism of regulation. Previous studies by Vasil and co-workers (6) have shown that under conditions of low iron hasA and hasR are co-transcribed from the hasR promoter. They further confirmed constitutive but weak transcription of hasA from an independent promoter within the intergenic region of hasR and hasA. However, these studies only addressed the effects of iron and not extracellular heme. In this study, we have confirmed heme-dependent transcriptional activation of the has operon, and based on current and previous studies, we propose a revised model for heme and BVIX-dependent regulation of heme uptake.
In this revised model under low iron conditions, hasR and hasA are co-transcribed from the hasR promoter. In addition, hasA is transcribed from the previously identified weak promoter within the intergenic region (6) . We have recently confirmed by 5Ј-rapid amplification of cDNA ends a hasA transcript originating from within the hasRA intergenic region (data not shown). This accounts for the differences in mRNA levels we observe in low iron or on addition of heme to the media. On encountering heme in the extracellular environment, the constitutively produced HasA activates the cell sur-face signaling system further up-regulating transcription of hasRA. We propose heme taken up by either the Has or Phu systems is degraded to BVIX␤ and BVIX␦, which function as post-transcriptional regulators of hasA. Thus, heme-dependent transcriptional activation of the cell surface signaling system, in combination with post-transcriptional regulation of the HasA signal by BVIX␤ and/or BVIX␦, allows the cell to rapidly respond to fluctuating extracellular heme levels. Although we presently do not understand the mechanism by which BVIX␤ and/or BVIX␦ post-transcriptionally regulate hasA, we propose this may be via a BVIX-specific ribosomal binding protein, an sRNA-dependent mechanism, or alternatively a BVIX-dependent riboswitch. Interestingly, within the intergenic region between hasR and hasA there is a previously predicted Rhoindependent terminator (6) that may function as a regulatory element. Furthermore, post-transcriptional BVIX␤/␦-dependent regulation of HasA provides a feedback loop coupling heme sensing by the Has system to the metabolic flux of heme through the PhuS-HemO couple. As shown previously, heme flux into the cell via the Has or Phu systems is driven by the catalytic activity of HemO and regulated by PhuS (12) . PhuS acts as a "stop valve" controlling heme flux through its specific interaction with HemO. Therefore, if heme flux is down-regulated due to irondependent suppression of HemO, the subsequent drop in BVIX␤ and BVIX␦ levels rapidly down-regulates heme sensing via HasA, irrespective of external heme levels. Conversely, if external levels of heme are extremely low, the decreased flux of heme through HemO maintains a constitutive low level expres-sion of HasA. To further address the mechanism by which BVIX␤ and BVIX␦ regulate heme uptake and utilization, we are constructing strains where the hemO ␣ and hemO in genes are integrated into the original hemO locus. This will allow transcriptional and translational fusion assays to be performed in the hemO ␣ and hemO in background without the complication of reduced BVIX levels.
Experimental Procedures
Bacterial Strains-All bacterial strains and plasmids used in this study are listed in Tables 2 and 3 , respectively. Escherichia coli strains were routinely grown in Luria Bertani (LB) broth (American Bioanalytical) or on LB agar plates, and P. aerugi- nosa strains were freshly streaked and maintained on Pseudomonas isolation agar (BD Biosciences). All strains were stored frozen at Ϫ80°C in LB broth with 20% glycerol. For BVIX metabolism, gene expression, and Western blotting analysis, a single isolated colony was inoculated into 10 ml of LB broth and grown overnight at 37°C. The bacteria were then harvested and washed in 10 ml of M9 minimal medium (Nalgene). Cells were harvested by centrifugation, and the bacterial pellet was resuspended in 10 ml of M9 medium as the initial inoculum into 50 ml of fresh M9 medium at a starting A 600 of 0.04. Cultures were grown at 37°C with shaking at 210 rpm for 3 h before supplementation with [ 13 C]heme at a final concen-tration of 0.5 M (time point 0) and incubated for 2, 5, or 7 h. When required, antibiotics were used at the following concentrations (g/ml): ampicillin, 100; tetracycline (Tc), 10 (for E. coli) and 150 (for P. aeruginosa); gentamicin (Gm), 200; carbenicillin (Cb), 500.
Construction of the Unmarked PAO1 ⌬hemO and Complemented Strains-The in-frame P. aeruginosa hemO mutant was constructed using two primer pairs, HemO-A/HemO-B and HemO-C/HemO-D (Table 3) , designed to amplify the amino and carboxyl termini of the gene from PAO1 genomic DNA. The gene sequence was confirmed by DNA sequencing (Eurofins MWG Operon). Following SacI-PstI digestion, the frag- ments were cloned into the counter-selective suicide plasmid pEX18Tc (17) . The resulting pEX18Tc⌬hemO was transformed into E. coli S17-1-pir, and a 0.8-kb KpnI fragment containing the FRT-Gm-FRT resistance cassette from pPS858 was inserted into the KpnI site of pEX18Tc⌬hemO. The resulting pEX18Tc-⌬hemO-GmFRT plasmid was transferred from E. coli S17-1-pir into P. aeruginosa PAO1 by conjugation. Clones in which a double event of homologous recombination resulted in the chromosomal integration of the ⌬hemO:: GmFRT allele were selected on PIA plates containing Gm and 5% sucrose. To obtain the unmarked ⌬hemO-deleted strain, the pFLP2 plasmid was mobilized into the PAO1 ⌬hemO::GmFRT strain. This plasmid encoding the Flippase recombinase (Flp) promotes recombination between FRT sequences flanking the Gm cassette. Isolated colonies were selected on PIA plates containing Cb, and loss of the hemO gene was confirmed by screening for Gm S . Plasmid pFLP2 was then cured by streaking Cb R Gm S colonies on PIA plates supplemented with 5% sucrose. Loss of pFLP2 was tested selecting for sucrose resistance and Cb S . Southern blotting hybridization, PCR, and sequencing analyses were used to verify allelic exchange of the parental gene and to ensure that the construct was non-polar (data not shown).
Complemented strains ⌬hemO::hemO wt , ⌬hemO::hemO ␣ , and ⌬hemO::hemO in were constructed by site-specific integra-tion into the attB locus in the ⌬hemO mutant strain (18) . Briefly, a 0.4-kb fragment encoding the hemO promoter region was PCR-amplified with primers PhemO/PhemOrev and cloned into the BamHI-EcoRI sites of mini-CTX1 plasmid to obtain the construct mini-CTX1-PhemO wt . The hemO ␣ and hemO in coding sequences were PCR-amplified with primer pair E-HemO/H-HemOrev using pBSP-HemO ␣ (19) and pET21a-HemO in (this study) as template, respectively. After EcoRI-Hin-dIII digestion, the 0.6-kb fragments were cloned into the mini-CTX1-PhemO, and the final constructs, mini-CTX1-hemO ␣ and mini-CTX1-hemO in , were confirmed by DNA sequencing. Recombinant plasmids were transferred from E. coli S17-1-pir into PAO1 ⌬hemO by conjugation. Screening for Tc R yielded derivatives containing the plasmid integrated into the CTX phage attB site of the P. aeruginosa chromosome. Excision of the unwanted plasmid DNA sequences was achieved by Flp recombinase as described previously (17, 18) . To verify the correct integration of complemented sequences at the ⌬hemO phage attachment (attB) site, this region was PCR-amplified from chromosomal DNA and sequenced by employing primers P ser-up and P ser-down (18) .
Site-directed Mutagenesis of the HemO-Site-directed mutagenesis was performed by PCR utilizing the QuikChange II mutagenesis kit and the previously constructed pET21a HemO expression plasmid (20) . Primers used to generate 
Name
Sequence and restriction site (enzyme) HemO H26A/K34A/K132A (HemO in ) and HemO N19K/ K34A/F117Y/K132A (HemO ␣ ) are listed in Table 3 . Mutations were verified by DNA sequencing (Eurofins MWG Operon).
RT-qPCR primers and probes
Purification and Characterization of HemO Wild Type and Mutant Proteins-Proteins were expressed and purified as described previously (20, 21) . The holo-HemO complexes and turnover experiments were performed as described previously (22) . The integrity of the secondary structure was determined by circular dichroism (CD) spectroscopy recorded on a Jasco J-810 spectropolarimeter. All samples were recorded in 20 mM potassium phosphate (pH 7.4) at 25°C from 19 to 260 nm at a scan rate of 20 nm/min, with each spectrum representing 10 accumulations. Data were acquired at 0.2-mm resolution and 1.0-cm bandwidth. The mean residue ellipticity (degrees cm 2 dmol Ϫ1 ) was calculated using CDPRO software as recommended by Jasco. Thermal denaturation studies were performed over a temperature range of 20 -90°C at 222 nm.
HemO-PhuS Protein-Protein Interaction as Measured by Isothermal Titration Calorimetry-Titrations were performed at 25°C using a MicroCal MCS titration calorimeter. All protein solutions were in 40 mM sodium phosphate buffer (pH 8.0). Samples were degassed before use and injections carried out at 5-min intervals. The heat of dilution of the protein was measured by injecting into the buffer alone. The value obtained was subtracted from the heat of reaction to give the effective heat of binding. Holo-PhuS was expressed and purified as described previously (23) . For all titration experiments, the concentration of holo-PhuS protein ranged from 20 to 30 M, and the titrated HemO variant was set to 10 -20 times this value. The ITC data were analyzed using the Origin software package provided by MicroCal. A nonlinear least squares algorithm (minimization of 2 ) was used to fit the heat flow per injection to an equation corresponding to an equilibrium binding model, which provides best fit values for the stoichiometry (n ITC ), change in enthalpy (⌬H ITC ), and binding constant (K ITC ). K D values and Gibbs free energy were calculated according to K d ϭ 1/K a and ⌬G ϭ ϪRT lnK a . The thermodynamic relationship ⌬G ϭ ⌬H Ϫ T⌬S was used to find the entropic contribution to binding. The data were averaged from three independent ITC experiments.
Preparation and Isolation of [ 12 C]Heme and [ 13 C]Heme-Unlabeled ␦-[ 12 C]aminolevulinic acid (ALA) was purchased from Frontier Scientific. Labeled ␦-[4-13 C]ALA was purchased from Cambridge Isotope Laboratories. [ 12 C]Heme or [ 13 C] heme was prepared by a slight modification of the method described by Rivera and Walker (24) and as reported previously (12, 19) . Briefly, mitochondrial rat cytochrome b 5 O, and 1 mM thiamine. Following lysis and centrifugation, the cellular lysate was loaded onto a Q-Sepharose anion exchange column (2.5 ϫ 10 cm) equilibrated in 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 50 mM NaCl. The column was washed with the same buffer followed by an additional wash with 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 125 mM NaCl (5 column volumes). Cytochrome b 5 was eluted in 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 250 mM NaCl and dialyzed over-night in 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 50 mM NaCl. Heme extraction from cytochrome b 5 was performed by the acid-butanone method as described previously (25) . Heme concentrations were determined by the pyridine hemochrome assay (26) . Heme stocks were prepared immediately prior to use by dissolving in 0.1 N NaOH and buffered to pH 7.4 with 1 M Tris-HCl, and the final concentration was determined by pyridine hemochrome (pH 7.4). As reported previously ␦-[4-13 C]ALA labeling shifts the heme mass by eight yielding distinct BVIX isomer fragmentation patterns shifted from the [ 12 C]BVIX fragment ions by mass ranges of ϩ2 to ϩ4 (11, 12, 17) .
Extraction of BVIX Isomers from P. aeruginosa Supernatants-Analysis of the BVIX isomers was performed by slight modification of the previously reported method (12, 19) . PAO1 WT and mutant strains supplemented with 0.5 M [ 13 C]heme were allowed to grow for 2, 5, and 7 h at 37°C in 250-ml baffled flasks with shaking. Culture supernatants following pelleting of the cells were filtered through a 0.2-m PES syringe filter, and 1 nM BVIX␣ dimethyl ester as an internal standard was added to each culture. The supernatant was acidified to pH ϳ3 with 10% trifluoroacetic acid (TFA). BVIX isomers were purified over a C 18 Sep-Pak column (Waters) as follows. The column was previously equilibrated with 2 ml of acetonitrile, 2 ml of methanol, 2 ml of water, and 2 ml of 10% methanol in 0.1% TFA (v/v). The supernatant was loaded on the column and washed with 4 ml of 0.1% (v/v) TFA, 4 ml of acetonitrile, 0.1% TFA (v/v 20:80), 2 ml of methanol, 0.1% TFA (50:50), and 450 l of methanol. BVIX isomers were eluted with additional 600 l of methanol, airdried, and stored at Ϫ80°C prior to LC-MS/MS analysis.
LC-MS/MS Analysis of P. aeruginosa BVIX Isomers-For LC-MS/MS analysis, samples were resuspended in 10 l of DMSO and diluted to 100 l with 90 l of H 2 O/acetonitrile (50:50). BVIX isomers were separated over an Ascentis RP-amide 2.7-m (C18) HPLC column (10 cm ϫ 2.1 mm) with a flow rate of 0.4 ml/min and analyzed on a Waters TQD triple quadrupole mass spectrometer with ACQUITY H-Class UPLC. Fragmentation patterns of the parent BVIX ions derived from [ 12 C]heme or [ 13 C]heme and the BVIX␣ dimethyl ester standard were analyzed using multiple reaction monitoring. The source temperature was set to 150°C, the capillary voltage to 3.6 kV, and the cone voltage to 75 V. The collision energy was set to 43 for the internal standard, 34 V for [ 12 C]BVIX␣ and [ 13 C]BVIX isomers, 30 V for [ 12 C]BVIX␤, and 36 V for [ 12 C]BVIX␦, respectively. Standard curves for quantification were prepared with known concentrations of each of the BVIX isomers. The lower and higher limits of quantification for all isomers were 0.001 and 150 M, respectively.
ICP-MS Analysis of Intracellular Iron Content-Aliquots (2 ml) were removed from cultures grown as described for the heme uptake studies at 2, 5, and 7 h, pelleted, and washed in fresh M9 media. The pellets were dissolved in trace-metal-free ultrapure 20% HNO 3 and boiled overnight at 100°C. Samples were further diluted with ultrapure water to a final concentration of 2% HNO 3 and subjected to ICP-MS on Agilent 7700 ICP-MS (Agilent Technologies). ICP-MS runs were calibrated with high purity iron standard solution (Sigma), and raw ICP-MS data (ppb) were corrected for drift using values for scandium and germanium (CPI International) as internal standards and added to samples during processing. Corrected values were then normalized to culture density as determined by the absorbance at 600 nm. Experimental values and reported standard deviation were the average of six biological replicates.
Expression Studies-Total RNA was purified from a 1-ml aliquot of 0-, 2-, 5-, and 7-h liquid cultures. RNA stabilization was conducted on-site using 250 l of RNALater Solution (Ambion), and samples were stored at Ϫ80°C until sample preparation. Total RNA was isolated from each cell pellet using the RNeasy mini spin columns according to the manufacturer's directions (Qiagen). Total RNA was treated with RNase-free DNase I (New England Biolabs) for 3 h at 37°C to remove contaminating chromosomal DNA and precipitated with 0.1ϫ volume 3 M sodium acetate (pH 5.2) and 2ϫ volume 100% (v/v) ethanol. RNA quantity and quality were assessed by UV absorption at 260 nm in a NanoDrop 2000c spectrophotometer (Thermo Scientific) and adjusted to 50 ng/l. cDNA was generated using the ImProm-II TM reverse transcription system (Promega) from a total of 50 ng of RNA and 0.5 g random primers. cDNA was analyzed using the StepOnePlus real time PCR system (Applied Biosystems) and TaqMan gene expression master mix (Applied Biosystems). The relative gene expression was calculated using the ⌬⌬Ct method, and the cycle threshold (Ct) values at the 0-, 2-, 5-, and 7-h time point were normalized to the constitutively expressed oprF gene. mRNA values represent the standard deviation of three independent experiments performed in triplicate. All primers and probes used for quantitative PCR studies are listed in Table 2 .
SDS-PAGE and Western Blotting Analysis-1-ml aliquots of PAO1 WT and mutant cultures were harvested at the 0-, 2-, 5-, and 7-h time points. Cell pellets were resuspended in 200 l per A 600 of 1.0 in Bugbuster (Novagen). Cells were incubated at room temperature for 30 min with occasional agitation to ensure complete cell lysis. Total protein concentrations were determined using the Bio-Rad RCDC assay. 25 g of total protein in 2ϫ SDS-loading buffer was run on 10% SDS-PAGE for PhuR or HasR detection, and 12% SDS-PAGE for PhuS, HemO, and HasA detection. Proteins were transferred by electrophoresis to a PVDF membrane (Bio-Rad). Membranes were blocked with blocking buffer (5% w/v skim milk in Tris-buffered saline (TBS) with 0.2% v/v Tween 20), washed, and probed with 1:750 dilution of anti-PhuR, anti-HasR, anti-HasA, anti-PhuS, or anti-HemO primary antibodies in hybridization buffer (1% w/v skim milk in TBS with 0.2% v/v Tween 20). Antibodies were obtained from Covance Custom Antibodies and generated from purified proteins supplied by our laboratory. Antibody specificity was checked against the respective purified proteins (10 ng), and all experimental Western blots were run with molecular weight markers as standards. RNA polymerase ␣ was probed as the loading control with the E. coli RNA polymerase primary antibody (BioLegend) at a dilution of 1:1000. Membranes were rinsed three times in TBS with 0.2% (v/v) Tween 20 and probed with goat anti-rabbit immunoglobulin G conjugated to horseradish peroxidase (KPL) at a dilution of 1:10,000 in hybridization buffer. Proteins were visualized by chemiluminescent detection using the SuperSignal chemiluminescence kit (Pierce) and hyperfilm ECL (Amer-sham Biosciences). The normalized density represents the relative abundance of each protein compared with RNA polymerase ␣ as the loading control for n ϭ 3 independent biological replicates. Densitometry analysis was performed on an AlphaImager HP System using the manufacturer's supplied AlphaView software. 
